Targeting cancer with best-in-class ADCs Solve is developing novel antibody-drug conjugates (ADCs) with high selectivity and optimized payload delivery enabled by CloakLink™, our proprietary hydrophilic linker system. Science Realizing the full potential of ADCs through precision engineering and innovation Our team’s approach to ADCs is grounded in a deep understanding of how each component of